Navigate our investors section.
This information has been disclosed pursuant to Rule 26 of the AIM Rules for Companies and was last updated on 28 March 2022.
See link to Investor Overview section.
See link to Board of Directors section.
See link to Board and Governance section.
See link to Key Corporate Documents section.
The company complies with the QCA Corporate Governance Code.
For further details, please see link to Board and Governance section
Celadon Pharmaceuticals Plc is incorporated in England and Wales and is listed solely on the London Stock Exchange Alternative Investment Market (AIM), and is subject to the UK City Code on Takeovers and Mergers.
TIDM: CEL.L
ISIN: GB00BDQYGP38
There are no restrictions on the transfer of Celadon Pharmaceutical’s shares.
The following information is correct as at 28 March 2022.
The Company’s issued share capital comprises 61,669,773 ordinary shares, each with a nominal value of 1 pence.
So far as the Company is aware, 70.6% of its issued share capital is not in public hands.
The Company has been notified of the following significant shareholders. Significant shareholders are those holding over 3% or more of the shares in issue.
| Name | Number of ordinary shares held | Percentage holding of total issued share capital |
|---|---|---|
| James Short | 26,046,928 | 42.2% |
| John Mitchell | 4,525,403 | 7.3% |
| Paul Allen | 4,525,403 | 7.3% |
| Cormac Short | 4,525,403 | 7.3% |
| Jonathan Rickard | 2,251,388 | 3.7% |
Last updated: 27th March 2022
In aggregate, the Directors of the Company Hold 27,424,072 shares, representing 44.5 per cent of the issued share capital of the Company.
| Name | Number of ordinary shares held | Percentage holding of total issued share capital |
|---|---|---|
| James Short (CEO) | 26,046,928 | 42.2% |
| Alexander Anton (Chairman) | 1,319,569 | 2.1% |
| Robert Barr (Senior Independant NED) | 45,454 | 0.07% |
| David Firth (NED) | 12,121 | 0.02% |
| Total | 27,424,072 | 44.5% |
Last updated: 27th March 2022
See link to Results and Presentations
See link to Regulatory News section
See link to 2022 Admission Document
Input your search keywords and press Enter.